Skip to main content

BLOOM — Bariatric Lymphedema One-Stage Operative Management (Sim)

BLOOM (Sim et al., Obesity Surgery 2025) is a novel single-stage combined procedure that simultaneously performs laparoscopic sleeve gastrectomy (LSG) for obesity and vascularized lymph node transfer (VLNT) for lymphedema by repurposing the gastroepiploic lymph nodes from the sleeve gastrectomy specimen — tissue that would otherwise be discarded. This is the first reported case combining bariatric and lymphedema surgery in a single operation.[1]

For the broader condition see Genital Lymphedema and Giant Penoscrotal Lymphedema. For canonical VLNT see Vascularized Lymph Node Transfer; for the LYST conceptual framework see LYST; for related SCIP-based options see 3R / SCIP-LFT, Complete Functional Lymphatic-System Pedicled Transfer, and CHASCIP; for debulking of the solid component see SAPL / Liposuction; for early-stage physiologic surgery see LVA; for the conservative anchor see Complex Decongestive Therapy.

Background and Rationale​

The obesity–lymphedema vicious cycle​

Obesity and lymphedema are bidirectionally linked:[2][3][4]

  1. Obesity impairs lymphatic function — excess mechanical pressure from adipose-tissue expansion compresses lymphatic vessels, reduces collecting-vessel pumping capacity, decreases lymphatic-endothelial-cell proliferation, increases lymphatic permeability, and triggers LN hypoplasia, fibrosis, and apoptosis.[2][3][5]
  2. Impaired lymphatic function worsens obesity — uncleared lymph fluid drives subcutaneous adipose deposition, fibrosis, and further weight gain.[2][6]
  3. Obesity-induced lymphedema (OIL) may emerge once BMI exceeds 40; lymphatic dysfunction is almost universal once BMI exceeds 60.[2]
  4. Elevated BMI is a well-established risk factor for cancer-related lymphedema and is associated with worse clinical course.[7][8]

Despite these clear links, obesity and lymphedema have traditionally been treated as separate conditions by separate specialties. BLOOM bridges that gap by treating both simultaneously.[1]

The gastroepiploic lymph node opportunity​

Sleeve gastrectomy already removes tissue containing functional lymph nodes along the greater curvature — the gastroepiploic / station-4d nodes. In standard LSG this tissue is discarded as surgical waste. BLOOM repurposes it as a vascularized lymph node flap.[1]

The gastroepiploic (omental) flap is one of the most widely used VLNT donors:[9][10][11]

  • Zero risk of donor-site lymphedema — omental nodes do not drain any extremity, so harvest cannot cause iatrogenic limb LE.[9]
  • Rich LN content — the proximal two-thirds of the gastroepiploic flap contains a mean of 6.5 ± 1.9 lymph nodes (95% of nodes within this region).[12]
  • Superior outcomes for lower-extremity LE — a 2026 meta-analysis (n = 395) found gastroepiploic flaps achieved significantly higher circumference reduction than other donors (p = 0.002 above knee; p < 0.001 below knee).[10]
  • Laparoscopic harvest is established, safe, and minimally invasive.[13][14]

The Index Case​

The first BLOOM procedure was performed on a 44-year-old female with BMI 35 and secondary lower-limb lymphedema. Simultaneous LSG + VLNT was performed using gastroepiploic lymph nodes harvested from the sleeve gastrectomy specimen. The patient recovered uneventfully with significant improvement in both BMI and lymphedema.[1]

Surgical Concept and Technique​

BLOOM integrates two established operations into a single anesthetic event.

Component 1 — Laparoscopic Sleeve Gastrectomy​

Standard LSG involves longitudinal resection of the greater curvature, starting 3–6 cm proximal to the pylorus and extending to the angle of His, leaving a tubular gastric sleeve along the lesser curvature.[15] The resected specimen includes:

  • The gastric fundus and body along the greater curvature.
  • The gastroepiploic vascular arcade along the greater curvature.
  • Perigastric station-4d lymph nodes embedded in the omental / perigastric fat along the right gastroepiploic artery (RGEA).

Component 2 — Gastroepiploic VLNT (repurposed from the sleeve specimen)​

Rather than discarding the resected tissue, the gastroepiploic lymph nodes and their vascular pedicle are harvested from the specimen and transferred to the lymphedematous extremity:[1][16][17]

  • RGEA pedicle — diameter 2.49 ± 0.66 mm at origin; mean ~4 cm to the first LN.
  • RGEV provides venous drainage.
  • The LN-bearing omental tissue is dissected from the specimen, preserving the vascular pedicle.
  • The flap is transferred to the recipient site (typically ankle, popliteal fossa, or groin) and microsurgically anastomosed to recipient vessels.

Anatomic Basis — Gastroepiploic LN Distribution​

Yoo et al. (2024) provided the most detailed anatomic study:[12]

Omental segmentCadaveric LN countGastrectomy-specimen LN count
Proximal third (near RGEA origin)2.54.9
Middle third1.42.7
Distal third0.50.7
Total4.48.3

Key findings:

  • 95% of lymph nodes are within the proximal two-thirds from the RGEA origin.[12]
  • The proximal third contains significantly more nodes than the distal third (p = 0.024 cadaveric; p = 0.016 gastrectomy specimens).[12]
  • In clinical VLNT cases the transferred flap measured 25.5 ± 6.9 × 4.1 ± 0.7 cm with a mean of 6.5 ± 1.9 lymph nodes.[12]
  • CTA planning — RGEA diameter 2.49 ± 0.66 mm at origin; LNs within 7.00 ± 6.2 mm of the artery.[16]

For BLOOM, the sleeve specimen includes the greater-curvature tissue where these nodes reside; the proximal (pyloric-end) portion of the specimen contains the highest LN density.[12]

Evidence Supporting the Gastroepiploic VLNT Component​

StudynDonor siteFollow-upKey outcomes
Shah et al. 2026 (meta-analysis)[10]395Multiple (GE superior)VariableCRR 24.79% (AK), 29.50% (BK); GE significantly superior (p = 0.002; p < 0.001)
Brown et al. 2022 (prospective)[9]89 (73% omentum)Omentum, axilla, supraclavicular, groin23.7 mo20% volume reduction; 93% cellulitis ↓; 34% off compression; 0% donor LE
Schaverien et al. 2021[18]134 (21 GE)Multiple24 mo45.7% volume reduction; 97.9% cellulitis ↓; no flap loss; outcomes similar across donors
Elia et al. 2022[19]89Single vs double GE-VLNT12–24 moDouble GE-VLNT — higher CRR (72.2% vs 70.6% AK; 61.6% vs 59.1% BK; p < 0.05); better QOL
Eaimkijkarn et al. 2026[14]12 (14 limbs)Laparoscopic omental27 mo29% circumference reduction; 93% flap survival; all lymphangitis resolved; lymphoscintigraphic improvement
Grünherz et al. 2024[11]70 (49 GE)GE, LTW, SIVariable9% volume loss (GE); significant QOL improvement; low donor morbidity

The omentum has become the preferred donor at many high-volume centers — Brown et al. used omentum in 73% of cases, noting it "does not have any donor-site lymphedema risk." Shah et al. concluded GE flaps should be "most used for lymphedema treatment" based on significantly superior CRR.[9][10]

The Dual Benefit — Why Combining Bariatric Surgery and VLNT Makes Biological Sense​

BLOOM addresses both arms of the obesity–lymphedema cycle simultaneously.

1. Weight loss improves lymphatic function​

Zhu et al. demonstrated that obesity causes acquired defects in lymphatic vasculature through mechanical pressure, pro-inflammatory cytokines, and adipokines that compromise collecting vessels and trigger LN hypoplasia. Weight reduction is the definitive management to restore lymphatic function before permanent vascular impairment develops.[3] Sudduth and Greene confirmed that the fundamental treatment for OIL is weight loss — it can reverse the unfavorable cycle of weight gain and lymphatic injury.[2]

2. VLNT restores lymphatic drainage​

Transferred gastroepiploic lymph nodes provide:

  • Neolymphangiogenesis — VEGF-C secretion drives new lymphatic-vessel formation. Eaimkijkarn et al. demonstrated enhanced drainage, reduced dermal backflow, and increased tracer uptake within transferred flaps on lymphoscintigraphy at 12 mo, confirming functional lymphatic integration.[14]
  • Lymph-node pump function — transferred nodes absorb interstitial fluid and channel it into the venous system.
  • Immune restoration — 93–97.9% reduction in cellulitis episodes across multiple series.[9][18]

3. Synergistic timing​

Performing both operations simultaneously means: lymphatic restoration begins at the same time as weight loss; one anesthetic event instead of two; lymph nodes are harvested fresh from the sleeve specimen with intact vascularity; and no additional donor-site morbidity — the nodes come from tissue that would otherwise be discarded.

Advantages of BLOOM​

AdvantageDetail
Single-stageEliminates two separate operations (bariatric + VLNT), reducing cumulative anesthetic risk, hospital stays, and recovery time[1]
Zero additional donor-site morbidityLNs harvested from the discarded sleeve specimen — no separate abdominal incision or laparoscopic entry for LN harvest[1]
Addresses both arms of the obesity–LE cycleWeight loss + lymphatic drainage restoration simultaneously[1][2][3]
Repurposes surgical wasteTransforms a discarded specimen into a therapeutic flap[1]
Best-evidenced VLNT donor siteGE site has 0% donor-LE risk and superior CRR vs other donors[9][10]
Multidisciplinary integrationBariatric surgeon + microsurgeon in the same OR[1]

Limitations and Considerations​

  • Single case report — BLOOM has been described in only one patient; reproducibility, complications, and long-term outcomes are unknown.[1]
  • No long-term follow-up data — "significant improvement" reported without quantitative volume, bioimpedance, or validated QOL scores.[1]
  • Patient selection criteria undefined — optimal BMI range, LE stage, and etiology for BLOOM candidacy not established. The index patient had BMI 35 (lower end of bariatric-surgery indications).[1]
  • Technical complexity — requires a bariatric surgeon and a microsurgeon and coordinated specimen handling, LN identification, and vascular-pedicle preservation from the sleeve specimen.[1]
  • Lymph-node viability concerns — standard GE-VLNT harvests nodes on an intact pedicle with preserved blood supply. In BLOOM the nodes are taken from the resected specimen, raising questions about:
    • Warm ischemia time after gastroepiploic vessels are divided during LSG.
    • Whether sufficient RGEA / RGEV pedicle length can be preserved for microanastomosis.
    • Whether LN number and function in the resected specimen match dedicated VLNT harvests.
  • BMI threshold for VLNT efficacy — most VLNT series include BMI 26–30. Whether VLNT is equally effective at BMI ≥ 35 (the BLOOM target population) is uncertain, since obesity itself impairs lymphatic function and may blunt the neolymphangiogenic response.[2][20]
  • Weight loss alone may suffice — the WISER Survivor RCT (n = 351) found 8.1% weight loss did not significantly improve interlimb volume difference in BCRL, though both limbs decreased; for OIL specifically, weight loss is the fundamental treatment and may suffice without VLNT in some cases.[2][7]

BLOOM vs Standard Sequential Approach​

FeatureBLOOM (Sim 2025)Standard sequential
Operations12 (bariatric → VLNT, or VLNT → bariatric)
Anesthetic events12
VLNT donorSleeve gastrectomy specimen (no additional harvest)Separate laparoscopic omental harvest or other donor
Additional donor-site morbidityNoneLaparoscopic port sites, potential GI complications
LN sourceGE nodes from resected greater curvatureGE nodes from intact omentum (standard VLNT)
Weight-loss + lymphatic-restoration timingSimultaneousSequential (months to years apart)
Evidence levelSingle case reportMultiple large series for each component separately
Multidisciplinary requirementBariatric surgeon + microsurgeon (same OR)Separate teams at different times
[1][9][12][13]

BLOOM vs Other "Repurposed Tissue" VLNT Concepts​

TechniqueConcurrent procedureRepurposed tissueApplication
BLOOM (Sim 2025)[1]Sleeve gastrectomyGE LNs from sleeve specimenLE LE + obesity
Zone-4 SCIP-LYST (Yoshimatsu 2022)[21]DIEP-flap breast reconstructionZone-4 lymphatic SCIP flap (normally discarded)BCRL prevention / treatment
Saaristo 2012[22]Modified lower-abdominal reconstructionLNs surrounding the SCIA pedicleBCRL treatment

All share the principle of harvesting lymphatic tissue from a concurrent procedure without additional donor-site morbidity — maximizing surgical efficiency and minimizing patient burden.

Potential Candidate Population​

Based on the BLOOM rationale and the obesity–LE literature, ideal candidates include:[1][2][3]

  1. BMI ≥ 35 with obesity-related comorbidities (meeting standard bariatric criteria) AND concurrent lymphedema.
  2. Secondary lower-extremity lymphedema (cancer-related or obesity-exacerbated) that has failed CDT.
  3. ISL Stage I–II disease (fluid component predominant) — where VLNT is most effective; advanced Stage III with massive fibroadipose burden may require additional debulking (liposuction).
  4. Patients who would otherwise require both bariatric surgery and VLNT.
  5. Patients with gynecologic or urologic cancer-related lymphedema who have developed secondary obesity — a common scenario where pelvic lymphadenectomy causes LE-LE and reduced mobility drives weight gain.

Future Directions​

  1. Prospective case series with standardized outcomes (limb volume, bioimpedance, LLIS, cellulitis rates, compression requirements) and ≥ 24-mo follow-up.[9]
  2. Formal LN-viability / VEGF-C-expression studies comparing sleeve-specimen vs standard VLNT harvest tissue.
  3. Optimal BMI range — determining whether BLOOM is most effective in Class I, II, or III obesity and whether the degree of weight loss correlates with LE improvement.
  4. Comparison with GLP-1 receptor agonists + VLNT — a clinically relevant comparator given the rapid adoption of semaglutide / tirzepatide.
  5. Extension to other bariatric procedures (RYGB) that also involve greater-curvature dissection.
  6. Standardization of specimen handling — protocols for LN identification, pedicle preservation, and warm-ischemia-time management during the transition from LSG to VLNT harvest.

Key Takeaways​

  1. BLOOM is the first reported combined bariatric + lymphedema operation, simultaneously performing sleeve gastrectomy and VLNT by repurposing gastroepiploic LNs from the sleeve specimen.[1]
  2. It addresses the bidirectional obesity–lymphedema cycle — weight loss reduces mechanical and inflammatory lymphatic impairment, while VLNT restores drainage.[1][2][3]
  3. Zero additional donor-site morbidity — LNs come from tissue that would otherwise be discarded.[1]
  4. The gastroepiploic donor has the strongest evidence base among VLNT donors — 0% donor-LE risk and significantly superior CRR for LE LE.[9][10]
  5. Current evidence is limited to a single case report — prospective series with standardized outcomes and long-term follow-up are required before BLOOM can be recommended as a standard approach.[1]
  6. The concept exemplifies emerging "repurposed tissue" VLNT — harvesting lymphatic tissue from concurrent procedures (sleeve gastrectomy, DIEP, etc.) without additional donor-site morbidity.[1]
  7. BLOOM requires multidisciplinary collaboration between bariatric surgeons and microsurgeons — a model that could be expanded to other combined procedures at the obesity–lymphedema intersection.[1]

References​

1. Sim NH, Ong LW, Yeo MSW, Yeung BP, Wong AW. Bariatric Lymphedema One-Stage Operative Management (BLOOM). Obes Surg. 2025;35(5):1860–1863. doi:10.1007/s11695-025-07847-z

2. Sudduth CL, Greene AK. Lymphedema and obesity. Cold Spring Harb Perspect Med. 2022;12(5):a041176. doi:10.1101/cshperspect.a041176

3. Zhu J, Wilding JPH, Hu J. Defective lymphatic vasculature in obesity. Obes Rev. 2025;26(8):e13922. doi:10.1111/obr.13922

4. De Nardo W, Chan AY, Porter CJH, Cao E, Trevaskis NL. Dysfunctional adipose tissue-lymphatic crosstalk in obesity. Nat Rev Endocrinol. 2026. doi:10.1038/s41574-026-01243-y

5. Castorena-Gonzalez JA. Lymphatic valve dysfunction in Western diet-fed mice: new insights into obesity-induced lymphedema. Front Pharmacol. 2022;13:823266. doi:10.3389/fphar.2022.823266

6. Cucchi F, Rossmeislova L, Simonsen L, Jensen MR, Bülow J. A vicious circle in chronic lymphoedema pathophysiology? An adipocentric view. Obes Rev. 2017;18(10):1159–1169. doi:10.1111/obr.12565

7. Schmitz KH, Troxel AB, Dean LT, et al. Effect of home-based exercise and weight loss programs on breast cancer–related lymphedema outcomes among overweight breast cancer survivors: the WISER Survivor randomized clinical trial. JAMA Oncol. 2019;5(11):1605–1613. doi:10.1001/jamaoncol.2019.2109

8. Rockson SG. Lymphedema after breast cancer treatment. N Engl J Med. 2018;379(20):1937–1944. doi:10.1056/NEJMcp1803290

9. Brown S, Mehrara BJ, Coriddi M, et al. A prospective study on the safety and efficacy of vascularized lymph node transplant. Ann Surg. 2022;276(4):635–653. doi:10.1097/SLA.0000000000005591

10. Shah P, Pillari B, Margiotta N, Devisetti N, Wong AK. Efficacy of vascularized lymph node transfer for lower extremity lymphedema: a systematic review and meta-analysis of 395 patients from 25 peer-reviewed studies. J Plast Reconstr Aesthet Surg. 2026;116:131–147. doi:10.1016/j.bjps.2026.03.005

11. Grünherz L, Barbon C, von Reibnitz D, et al. Analysis of different outcome parameters and quality of life after different techniques of free vascularized lymph node transfer. J Vasc Surg Venous Lymphat Disord. 2024;12(6):101934. doi:10.1016/j.jvsv.2024.101934

12. Yoo H, Hong KY, Min S, et al. Distribution of perigastric station 4d lymph nodes in vascularized gastroepiploic lymph node transfer: an anatomic study and case series. Ann Surg Oncol. 2024;31(6):3694–3704. doi:10.1245/s10434-024-15113-2

13. Johnston ME, Socas J, Hunter JL, Ceppa EP. Laparoscopic gastroepiploic lymphovascular pedicle harvesting for the treatment of extremity lymphedema: a novel technique. Surg Laparosc Endosc Percutan Tech. 2017;27(3):e40–e43. doi:10.1097/SLE.0000000000000412

14. Eaimkijkarn C, Kanasup N, Rattanamahattana O, et al. Laparoscopic omental lymph node flap transfer for lower extremity lymphedema: insights into lymphangiogenesis and clinical outcomes. Int J Med Sci. 2026;23(2):720–729. doi:10.7150/ijms.125568

15. Steenackers N, Vanuytsel T, Augustijns P, et al. Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass. Lancet Gastroenterol Hepatol. 2021;6(3):225–237. doi:10.1016/S2468-1253(20)30302-2

16. Howell AC, Gould DJ, Mayfield C, et al. Anatomical basis of the gastroepiploic vascularized lymph node transfer: a radiographic evaluation using computed tomographic angiography. Plast Reconstr Surg. 2018;142(4):1046–1052. doi:10.1097/PRS.0000000000004772

17. Settembre N, Labrousse M, Magnan PE, et al. Surgical anatomy of the right gastro-omental artery: a study on 100 cadaver dissections. Surg Radiol Anat. 2018;40(4):415–422. doi:10.1007/s00276-017-1951-7

18. Schaverien MV, Asaad M, Selber JC, et al. Outcomes of vascularized lymph node transplantation for treatment of lymphedema. J Am Coll Surg. 2021;232(6):982–994. doi:10.1016/j.jamcollsurg.2021.03.002

19. Elia R, Chen HC, Taranto GD, et al. Gastroepiploic vascularized lymph node transfer for extremities' lymphedema: is two better than one? A retrospective case-control study. J Plast Reconstr Aesthet Surg. 2022;75(9):3129–3137. doi:10.1016/j.bjps.2022.04.105

20. Garza RM, Beederman M, Chang DW. Physical and functional outcomes of simultaneous vascularized lymph node transplant and lymphovenous bypass in the treatment of lymphedema. Plast Reconstr Surg. 2022;150(1):169–180. doi:10.1097/PRS.0000000000009247

21. Yoshimatsu H, Karakawa R, Fuse Y, Yano T. Simultaneous lymphatic superficial circumflex iliac artery perforator flap transfer from the Zone 4 region in autologous breast reconstruction using the deep inferior epigastric artery perforator flap: a proof-of-concept study. J Clin Med. 2022;11(3):534. doi:10.3390/jcm11030534

22. Saaristo AM, Niemi TS, Viitanen TP, et al. Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients. Ann Surg. 2012;255(3):468–473. doi:10.1097/SLA.0b013e3182426757